




Instance: composition-en-6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: CompositionUvEpi
Title: "Composition for kinpeygo Package Leaflet"
Description:  "Composition for kinpeygo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1657/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6dd92eeff0b9acf2637c14b216fa6b97)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - kinpeygo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Kinpeygo is and what it is used for  </li>
<li>What you need to know before you take Kinpeygo  </li>
<li>How to take Kinpeygo  </li>
<li>Possible side effects  </li>
<li>How to store Kinpeygo  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What kinpeygo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What kinpeygo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kinpeygo contains the active substance budesonide, a corticosteroid medicine which mainly acts 
locally in the intestine to reduce the inflammation associated with primary immunoglobulin A (IgA) 
nephropathy. </p>
<p>Kinpeygo is used to treat primary IgA nephropathy in adults 18 years of age or older.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Kinpeygo:</p>
<ul>
<li>If you are allergic to budesonide or any of the other ingredients of this medicine (listed in 
section 6).  </li>
<li>If you have loss of function of your liver that your doctor has told you is  severe . </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Kinpeygo: 
* If you are going to have surgery. 
* If you have liver problems. 
* If you are taking or have recently taken corticosteroids. 
* If you have recently had an infection.<br />
* If you have active or quiescent tuberculosis infection, untreated fungal, bacterial, systemic viral 
or parasitic infections, or ocular herpes simplex. 
* If you have high blood pressure. 
* If you have diabetes   or someone in your family has had diabetes. 
* If you have brittle bones (osteoporosis). 
* If you have stomach ulcers. 
* If you have glaucoma (increased pressure in the eye)  or cataracts   or someone in your family 
has had glaucoma (increased   pressure in the eye). </p>
<p>If any of the above apply to you, you may be at increased risk of side effects. Your doctor will decide 
on the appropriate measures and if it is still all right for you to take this medicine. </p>
<p>Look out for side effects 
If you get blurred vision or other sight problems, contact your doctor. See section 4 for more 
information. </p>
<p>Chickenpox or measles 
Illnesses like chickenpox and measles can be more serious if you are taking this medicine. If you have 
not yet had these illnesses, keep away from people with chicken pox or measles while taking this 
medicine. Tell your doctor if you think that you have been infected with chicken pox or measles while 
taking this medicine. </p>
<p>Adrenal function tests 
Kinpeygo could affect the results of adrenal function tests (ACTH stimulation test) ordered by your 
doctor. Tell your doctors that you are taking Kinpeygo before you have any tests.  </p>
<p>Children and adolescents 
Kinpeygo should not be used in children and adolescents below 18 years of age. The use of this 
medicine in children younger than 18 years of age has not been studied. </p>
<p>Other medicines and Kinpeygo 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This includes medicines obtained without a prescription, and herbal medicines. </p>
<p>This is because Kinpeygo capsules can affect the way some medicines work and some medicines can 
have an effect on Kinpeygo capsules. </p>
<p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:<br />
<em> Ketoconazole or itraconazole - to treat infections caused by a fungus.<br />
</em> Medicines for HIV called  protease inhibitors  - such as ritonavir, indinavir and saquinavir. <br />
<em> Erythromycin - an antibiotic used to treat infections.<br />
</em> Cyclosporin - used to suppress your immune system. 
* Carbamazepine - for epilepsy and nerve pain problems. 
* Cardiac glycosides - such as digoxin- medicines used to treat heart conditions. 
* Diuretics - to remove excess fluid from the body. </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking 
Kinpeygo. </p>
<p>Kinpeygo with food and drink 
Do not eat grapefruit or drink grapefruit juice while you are taking Kinpeygo. It can affect the way the 
medicine works. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Do not take this medicine during pregnancy without checking with your doctor first. </p>
<p>Do not take this medicine if you are breast-feeding unless you have checked with your doctor. 
Budesonide passes in small amounts into the breast milk. Your doctor will help you decide whether 
you should continue treatment and not breast-feed or if you should stop treatment over the period your 
baby is being breast-fed.  </p>
<p>Driving and using machines 
Kinpeygo is not expected to affect your ability to drive or use any machines. </p>
<p>Kinpeygo contains sucrose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>How to take 
The recommended dose of Kinpeygo is 16 mg (4 capsules of Kinpeygo 4 mg) once daily. 
Take in the morning, at least 1 hour before a meal.<br />
* Swallow whole with a glass of water. 
* Do not open, crush or chew   as this could affect the release of the medicine. The capsules have 
a special coating, to ensure that the medicine is released in the correct part of your gut.  </p>
<p>When treatment is to be discontinued, your doctor will reduce the dose to 8 mg (2 capsules of 
Kinpeygo 4 mg) once daily for the last 2 weeks of therapy. If considered necessary by your doctor, the 
dose may then be reduced to 4 mg once daily (1 capsule of Kinpeygo 4 mg) for another 2 weeks. </p>
<p>If you take more Kinpeygo than you should 
If you take more Kinpeygo than you should, talk to a doctor or pharmacist straight away. Take the 
carton with you.  </p>
<p>If you have taken more than you should for a long time, the possible side effects listed in section 4 
may appear. </p>
<p>If you forget to take Kinpeygo 
If you miss a dose of Kinpeygo, wait and take the medicine the next day as usual.<br />
Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Kinpeygo 
Do not stop taking Kinpeygo without discussing it with your doctor first. If you suddenly stop taking 
the medicine, you may become ill. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor if you notice any of the following side effects with this medicine: </p>
<p>Common (may affect up to 1 in 10 people)  </p>
<ul>
<li>Increased blood pressure </li>
<li>Swelling of arms or legs   such as ankle swelling </li>
<li>Cushingoid features such as a rounded face, increased body hair, weight gain and acne  </li>
<li>Indigestion  </li>
<li>Muscle cramps </li>
<li>Rash or itchy skin </li>
<li>Weight gain </li>
<li>Diabetes mellitus </li>
</ul>
<p>Rare (may affect up to 1 in 1 000 people)  </p>
<ul>
<li>Blurred vision  </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V.* By reporting side effects you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle label. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Kinpeygo contains<br />
- The active substance is budesonide. Each modified-release hard capsule contains 4 mg of 
budesonide. </p>
<ul>
<li>The other ingredients are: 
Capsule content: Sugar spheres (sucrose and corn starch), hypromellose, macrogol, citric acid 
monohydrate, ethylcellulose, medium chain triglycerides, oleic acid (see also section 2  Kinpeygo 
contains sucrose ). 
Capsule shell: Hypromellose, macrogol, titanium dioxide (E171), methacrylic acid-methyl 
methacrylate co-polymers, talc, dibutyl sebacate,<br />
Printing ink: Shellac, black iron oxide (E172). </li>
</ul>
<p>What Kinpeygo looks like and contents of the pack 
Kinpeygo 4 mg modified-release hard capsules are 19 mm white coated opaque capsules printed with 
 CAL10 4MG  in black ink. </p>
<p>The capsules are supplied in a white high-density polyethylene (HDPE) bottle with a white 
polypropylene (PP) child-resistant closure with an induction seal. 
This medicine is available in bottles containing 120 modified-release hard capsules and in multipacks 
of 360 modified-release hard capsules comprising 3 bottles, each containing 120 modified-release hard 
capsules. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
STADA Arzneimittel AG 
Stadastrasse 2-61118 Bad Vilbel 
Germany  </p>
<p>Manufacturer  </p>
<p>Tjoapack Netherlands B.V. 
Nieuwe Donk 9 
4879 AC Etten-Leur 
Noord-Brabant 
Netherlands </p>
<p>STADA Arzneimittel AG<br />
Stadastrasse 2   61118 Bad Vilbel<br />
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder :  </p>
<p>Belgi /Belgique/Belgien<br />
EG (Eurogenerics) NV<br />
T l/Tel: +32 24797Lietuva<br />
UAB  STADA Baltics<br />
Tel: +370 52603 <br />
STADA Bulgaria EOOD<br />
Te .: +359 29624Luxembourg/Luxemburg<br />
EG (Eurogenerics) NV<br />
T l/Tel: +32 24797 esk  republika<br />
STADA PHARMA CZ s.r.o. 
Tel: +420 257888Magyarorsz g<br />
STADA Hungary Kft<br />
Tel.: +36 18009Danmark 
STADA Nordic ApS 
Tlf: +45 44859Malta 
Pharma.MT Ltd. 
Tel: + 356 21337Deutschland<br />
STADAPHARM GmbH<br />
Tel: +49 61016Nederland<br />
Centrafarm B.V.<br />
Tel.: +31 765081Eesti 
UAB  STADA Baltics <br />
Tel: +370 52603Norge<br />
STADA Nordic ApS 
Tlf: +45 44859<br />
F RAN S.A. 
 : +30 2106254 sterreich 
STADA Arzneimittel GmbH<br />
Tel: +43 136785Espa a 
Laboratorio STADA, S.L.<br />
Tel: +34 934738Polska 
STADA Poland Sp. z o.o. 
Tel: +48 227377France 
EG Labo - Laboratoires EuroGenerics<br />
T l: +33 146948Portugal 
Stada, Lda. 
Tel: +351 211209Hrvatska 
STADA d.o.o. 
Tel: +385 13764Rom nia 
STADA M&amp;D SRL<br />
Tel: +40 213160Ireland 
Clonmel Healthcare Ltd.<br />
Tel: +353 526177Slovenija 
Stada d.o.o. 
Tel: +386 15896 sland 
STADA Nordic ApS 
 Tlf: +45 44859Slovensk  republika 
STADA PHARMA Slovakia, s.r.o.<br />
Tel: +421 252621Italia 
EG SpA 
Tel: +39 028310Suomi/Finland 
STADA Nordic ApS, Suomen sivuliike<br />
Puh/Tel: +358 207416<br />
STADA Arzneimittel AG<br />
 : +30 2106664Sverige 
STADA Nordic ApS<br />
Tel: +45 44859Latvija 
UAB  STADA Baltics <br />
Tel: +370 52603United Kingdom (Northern Ireland) 
STADA Arzneimittel AG<br />
Tel: +49 61016This leaflet was last revised in 07/2023 .  </p>
<p>This medicine has been given  conditional approval . This means that there is more evidence to come 
about this medicine. </p>
<p>The European Medicines Agency will review new information on this medicine at least every year and 
this leaflet will be updated as necessary. </p>         </div>"""      



Instance: composition-da-6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: CompositionUvEpi
Title: "Composition for kinpeygo Package Leaflet"
Description:  "Composition for kinpeygo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1657/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6dd92eeff0b9acf2637c14b216fa6b97)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - kinpeygo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Kinpeygo </li>
<li>Sådan skal du tage Kinpeygo </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What kinpeygo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What kinpeygo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kinpeygo indeholder det aktive stof budesonid, som er et binyrebarkhormon, der hovedsagelig virker 
lokalt i tarmen ved at reducere den betændelse, der er forbundet med primær immunglobulin A (IgA)-
nefropati. </p>
<p>Kinpeygo anvendes til behandling af primær IgA-nefropati hos voksne på 18 år eller derover. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Kinpeygo:</p>
<ul>
<li>Hvis du er allergisk over for budesonid eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). </li>
<li>Hvis du har nedsat leverfunktion, og lægen har sagt, at den er "svært nedsat". </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Kinpeygo: </p>
<ul>
<li>
<p>Hvis du skal opereres. </p>
</li>
<li>
<p>Hvis du har leverproblemer. </p>
</li>
<li>
<p>Hvis du tager eller for nylig har taget kortikosteroider. </p>
</li>
<li>
<p>Hvis du for nylig har haft en infektion. </p>
</li>
<li>
<p>Hvis du har en aktiv eller mindre alvorlig tuberkuloseinfektion, en ubehandlet svampe- eller 
bakterieinfektion, en systemisk virus- eller parasitinfektion eller okulær herpes simplex. </p>
</li>
<li>
<p>Hvis du har forhøjet blodtryk. </p>
</li>
<li>
<p>Hvis du har diabetes - eller hvis nogen i din familie har haft diabetes. </p>
</li>
<li>
<p>Hvis du har skrøbelige knogler (osteoporose). </p>
</li>
<li>
<p>Hvis du har mavesår. </p>
</li>
<li>
<p>Hvis du har grøn stær (forhøjet tryk i øjet) eller grå stær - eller nogen i din familie har haft grøn 
stær (forhøjet tryk i øjet). </p>
</li>
</ul>
<p>Hvis noget af ovenstående gælder for dig, kan du have øget risiko for bivirkninger. Lægen vil afgøre, 
hvilke forholdsregler der skal træffes, og om det stadig er bedst for dig at tage dette lægemiddel. </p>
<p>Vær opmærksom på bivirkninger 
Hvis du oplever sløret syn eller andre synsforstyrrelser, skal du kontakte lægen. Se punkt 4 for 
yderligere oplysninger. </p>
<p>Skoldkopper eller mæslinger 
Sygdomme som skoldkopper og mæslinger kan være mere alvorlige, hvis du tager dette lægemiddel. 
Hvis du endnu ikke har haft disse sygdomme, skal du holde dig væk fra personer med skoldkopper 
eller mæslinger, mens du tager dette lægemiddel. Fortæl det til lægen, hvis du tror, du er blevet smittet 
med skoldkopper eller mæslinger, mens du tog dette lægemiddel. </p>
<p>Test af binyrebarkfunktion 
Kinpeygo kan påvirke resultaterne ved en test af binyrebarkfunktion (ACTH-stimulationstest), som 
din læge har bestilt. Fortæl lægen, at du tager Kinpeygo, før du får udført en test. </p>
<p>Børn og unge 
Kinpeygo bør ikke anvendes hos børn og unge under 18 år. Brugen af dette lægemiddel hos børn 
under 18 år er ikke blevet undersøgt. </p>
<p>Brug af anden medicin sammen med Kinpeygo 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for 
nylig. Dette gælder også medicin, som ikke er købt på recept, og naturlægemidler. </p>
<p>Det skyldes, at Kinpeygo-kapsler kan påvirke den måde, visse lægemidler virker på, og visse 
lægemidler kan påvirke Kinpeygo-kapslerne. </p>
<p>Det er især vigtigt, at du fortæller det til lægen eller apotekspersonalet, hvis du i forvejen tager et af 
nedenstående lægemidler: </p>
<ul>
<li>
<p>Ketoconazol eller itraconazol - til behandling af svampeinfektioner. </p>
</li>
<li>
<p>Lægemidler mod hiv, der kaldes "proteasehæmmere" - f.eks. ritonavir, indinavir og saquinavir. </p>
</li>
<li>
<p>Erythromycin - et antibiotikum, der anvendes til behandling af infektioner. </p>
</li>
<li>
<p>Ciclosporin - der anvendes til at undertrykke dit immunsystem. </p>
</li>
<li>
<p>Carbamazepin - mod epilepsi og nervesmerter. </p>
</li>
<li>
<p>Hjerteglykosider - såsom digoxiner - til behandling af hjertesygdomme. </p>
</li>
<li>
<p>Diuretika - til fjernelse af overskydende væske fra kroppen. </p>
</li>
</ul>
<p>Hvis noget af ovenstående gælder for dig (eller hvis du er i tvivl), skal du tale med lægen eller 
apotekspersonalet, før du tager Kinpeygo. </p>
<p>Brug af Kinpeygo sammen med mad og drikke 
Du må ikke spise grapefrugt eller drikke grapefrugtjuice, mens du tager Kinpeygo. Det kan påvirke 
lægemidlets virkemåde. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge lægen eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Tag ikke dette lægemiddel under graviditet uden først at have talt med lægen. </p>
<p>Tag ikke dette lægemiddel, hvis du ammer, medmindre du har talt med lægen. Budesonid går i små 
mængder over i modermælken. Din læge vil hjælpe dig med at beslutte, om du skal fortsætte 
behandlingen og ikke amme, eller om du skal stoppe behandlingen i den periode, hvor du ammer dit 
barn. </p>
<p>Evne til at føre motorkøretøj og betjene maskiner 
Kinpeygo forventes ikke at påvirke din evne til at føre motorkøretøj eller betjene maskiner. </p>
<p>Kinpeygo indeholder saccharose 
Hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter, skal du tale med lægen, før du tager dette 
lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Sådan skal du tage Kinpeygo 
Den anbefalede dosis af Kinpeygo er 16 mg (4 kapsler Kinpeygo 4 mg) én gang dagligt. 
Tages om morgenen mindst 1 time før et måltid. </p>
<ul>
<li>
<p>Synkes hele med et glas vand. </p>
</li>
<li>
<p>Må ikke åbnes, knuses eller tygges, da dette kan påvirke lægemidlets udløsning. Kapslerne har 
et særligt overtræk for at sikre, at lægemidlet udløses i den korrekte del af tarmen. </p>
</li>
</ul>
<p>Når behandlingen skal seponeres, vil lægen nedsætte dosis til 8 mg (2 kapsler Kinpeygo 4 mg) én gang 
dagligt i de sidste 2 ugers behandling. Hvis lægen finder det nødvendigt, kan dosen derefter reduceres 
til 4 mg én gang dagligt (1 kapsel Kinpeygo 4 mg) i yderligere 2 uger. </p>
<p>Hvis du har taget for meget Kinpeygo 
Hvis du har taget for meget Kinpeygo, skal du straks tale med lægen eller apotekspersonalet. Tag 
æsken med dig. </p>
<p>Hvis du har taget for meget igennem længere tid, kan de mulige bivirkninger, der er nævnt i punkt 4, 
forekomme. </p>
<p>Hvis du har glemt at tage Kinpeygo 
Hvis du glemmer en dosis af Kinpeygo, skal du vente og tage lægemidlet den næste dag som normalt. 
Du må ikke tage en dobbeltdosis som erstatning for en glemt dosis. </p>
<p>Hvis du holder op med at tage Kinpeygo 
Du må ikke holde op med at tage Kinpeygo uden først at have talt med lægen om det. Hvis du 
pludselig holder op med at tage lægemidlet, kan du blive syg. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det til lægen, hvis du bemærker en eller flere af følgende bivirkninger ved dette lægemiddel: </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) </p>
<ul>
<li>
<p>Forhøjet blodtryk </p>
</li>
<li>
<p>Hævede arme eller ben - f.eks. hævede ankler </p>
</li>
<li>
<p>Cushingoide træk, f.eks. et rundt ansigt, øget hårvækst, vægtforøgelse og akne </p>
</li>
<li>
<p>Fordøjelsesbesvær </p>
</li>
<li>
<p>Muskelkramper </p>
</li>
<li>
<p>Udslæt eller kløende hud </p>
</li>
<li>
<p>Vægtøgning </p>
</li>
<li>
<p>Diabetes mellitus </p>
</li>
</ul>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1 000 patienter) </p>
<ul>
<li>Sløret syn </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, skal du tale med din læge eller apoteket. Det gælder også bivirkninger, 
der ikke er nævnt i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store kinpeygo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store kinpeygo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og flaskeetiketten. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25 °C.  </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg på 
apoteket, hvordan du skal bortskaffe medicinrester. Dette vil være med til at skåne miljøet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kinpeygo indeholder:</p>
<ul>
<li>
<p>Aktivt stof: budesonid. Hver hård kapsel med modificeret udløsning indeholder 4 mg 
budesonid. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Kapselindhold: Sukkerkugler (saccharose og majsstivelse), hypromellose, macrogol, 
citronsyremonohydrat, ethylcellulose, triglycerider med middel kædelængde, oliesyre (se også punkt 2 
"Kinpeygo indeholder saccharose"). 
Kapselskal: Hypromellose, macrogol, titandioxid (E171), methacrylsyre-methyl-
methacrylatcopolymerer, talkum, dibutylsebacat. 
Trykfarve: Shellac, sort jernoxid (E172). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Kinpeygo 4 mg hårde kapsler med modificeret udløsning er 19 mm hvide, uigennemsigtige kapsler 
påtrykt "CAL10 4MG" med sort blæk. </p>
<p>Kapslerne leveres i en hvid flaske af højdensitetspolyetylen (HDPE) med et hvidt børnesikret låg af 
polypropylen (PP) med induktionsforsegling. 
Dette lægemiddel er tilgængeligt i flasker indeholdende 28, 100, 120 hårde kapsler med modificeret 
frigivelse og i multipakninger med 360 hårde kapsler med modificeret frigivelse, bestående af 3 
flasker, som hver indeholder 120 hårde kapsler med modificeret frigivelse. </p>
<p>Ikke alle pakningsstørrelser er muligvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
STADA Arzneimittel AG 
Stadastrasse 2-61118 Bad Vilbel 
Tyskland  </p>
<p>Fremstiller 
Tjoapack Netherlands B.V. 
Nieuwe Donk 9 
4879 AC Etten-Leur 
Noord-Brabant 
Nederlandene </p>
<p>STADA Arzneimittel AG 
Stadastrasse 2-61118 Bad Vilbel 
Tyskland  </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale<br />
repræsentant for indehaveren af markedsføringstilladelsen : </p>
<p>België/Belgique/Belgien<br />
EG (Eurogenerics) NV<br />
Tél/Tel: +32 24797Lietuva<br />
UAB „STADA Baltics“ 
Tel: +370 52603 </p>
<p>България<br />
STADA Bulgaria EOOD<br />
Teл.: +359 29624Luxembourg/Luxemburg<br />
EG (Eurogenerics) NV<br />
Tél/Tel: +32 24797 </p>
<p>Česká republika<br />
STADA PHARMA CZ s.r.o. 
Tel: +420 257888Magyarország<br />
STADA Hungary Kft<br />
Tel.: +36 18009 </p>
<p>Danmark 
STADA Nordic ApS 
Tlf: +45 44859Malta 
Pharma.MT Ltd. 
Tel: + 356 21337 </p>
<p>Deutschland<br />
STADAPHARM GmbH<br />
Tel: +49 61016Nederland<br />
Centrafarm B.V.<br />
Tel.: +31 765081 </p>
<p>Eesti 
UAB „STADA Baltics“<br />
Tel: +370 52603Norge<br />
STADA Nordic ApS 
Tlf: +45 44859 </p>
<p>Ελλάδα 
FΑRAN S.A. 
Τηλ: +30 2106254 
Österreich 
STADA Arzneimittel GmbH<br />
Tel: +43 136785 </p>
<p>España 
Laboratorio STADA, S.L.<br />
Tel: +34 934738Polska 
STADA Poland Sp. z o.o. 
Tel: +48 227377 </p>
<p>France 
Portugal 
EG Labo - Laboratoires EuroGenerics 
Tél: +33 146948Stada, Lda. 
Tel: +351 211209Hrvatska 
STADA d.o.o. 
Tel: +385 13764România 
STADA M&amp;D SRL<br />
Tel: +40 213160Ireland 
Clonmel Healthcare Ltd. 
Tel: +353 526177Slovenija 
Stada d.o.o. 
Tel: +386 15896Ísland 
STADA Nordic ApS 
 Tlf: +45 44859Slovenská republika 
STADA PHARMA Slovakia, s.r.o. 
Tel: +421 252621Italia 
EG SpA 
Tel: +39 028310Suomi/Finland 
STADA Nordic ApS, Suomen sivuliike 
Puh/Tel: +358 207416Κύπρος 
STADA Arzneimittel AG 
Τηλ: +30 2106664Sverige 
STADA Nordic ApS 
Tel: +45 44859Latvija 
UAB „STADA Baltics“ 
Tel: +370 52603United Kingdom (Northern Ireland) 
STADA Arzneimittel AG<br />
Tel: +49 61016Denne indlægsseddel blev senest ændret 
Dette lægemiddel er godkendt under "betingede omstændigheder". Det betyder, at der forventes 
yderligere dokumentation for lægemidlet. 
Det Europæiske Lægemiddelagentur vil mindst en gang om året vurdere nye oplysninger om 
lægemidlet, og denne indlægsseddel vil om nødvendigt blive opdateret. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for kinpeygo Package Leaflet for language en"
Description: "ePI document Bundle for kinpeygo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6dd92eeff0b9acf2637c14b216fa6b97"
* entry[0].resource = composition-en-6dd92eeff0b9acf2637c14b216fa6b97

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6dd92eeff0b9acf2637c14b216fa6b97"
* entry[=].resource = mp6dd92eeff0b9acf2637c14b216fa6b97
                            
                    
Instance: bundlepackageleaflet-da-6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for kinpeygo Package Leaflet for language da"
Description: "ePI document Bundle for kinpeygo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6dd92eeff0b9acf2637c14b216fa6b97"
* entry[0].resource = composition-da-6dd92eeff0b9acf2637c14b216fa6b97

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6dd92eeff0b9acf2637c14b216fa6b97"
* entry[=].resource = mp6dd92eeff0b9acf2637c14b216fa6b97
                            
                    



Instance: mp6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Kinpeygo 4 mg modified-release hard capsules"
Description: "Kinpeygo 4 mg modified-release hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1657/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Kinpeygo 4 mg modified-release hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6dd92eeff0b9acf2637c14b216fa6b97ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "kinpeygo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with kinpeygo"

* subject = Reference(mp6dd92eeff0b9acf2637c14b216fa6b97)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#kinpeygo "kinpeygo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6dd92eeff0b9acf2637c14b216fa6b97) // kinpeygo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6dd92eeff0b9acf2637c14b216fa6b97) // kinpeygo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6dd92eeff0b9acf2637c14b216fa6b97
InstanceOf: List

* insert 6dd92eeff0b9acf2637c14b216fa6b97ListRuleset
    